A Double-Blind Randomized Crossover Trial to Define the Ecg Effects of Droxidopa Using a Clinical and a Supratherapeutic Dose Compared With Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: a Thorough Ecg Trial

Trial Profile

A Double-Blind Randomized Crossover Trial to Define the Ecg Effects of Droxidopa Using a Clinical and a Supratherapeutic Dose Compared With Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: a Thorough Ecg Trial

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Droxidopa (Primary) ; Moxifloxacin
  • Indications Attention-deficit hyperactivity disorder; Bacterial infections; Fibromyalgia; Orthostatic hypotension; Parkinson's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 19 May 2015 Pooled analysis (102,301,306) cardiac repolarization results presented at the 30th Annual Scientific Meeting of the American Society of Hypertension.
    • 03 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Jun 2011 Results have been reported in a Chelsea Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top